IL15RA and prostate carcinoma: Moreover, TS/A breast and TRAMP-C2 prostate cancer cells engineered to co-express IL-15 and IL-15Rα showed a lower growth after subcutaneous injection in syngeneic mice and were also effective as a vaccine activating immune responses (mainly mediated by CD8+ and NK cells), which delayed the growth of tumor cell challenges [43].